Takeda CEO facing pressure amid dismal profits — 4 key notes

Takeda Pharmaceuticals President and CEO Christophe Weber could face increased scrutiny after the retirement of Chairman Yasuchika Hasegawa, Biospace.com reports. 

Here's what you should know:

1. Mr. Hasegawa was supposed to assume a corporate councilor position following his retirement, but the company's stakeholders rejected the appointment after Takeda posted "dismal" earnings.

2. Mr. Hasegawa was often advocated for Mr. Weber according to the Nikkei Asian Review.

3. Mr. Weber is facing criticism over Takeda's falling profitability, recent acquisitions and decreased research-and-development efforts.

4. Takeda has pivoted towards acquiring drug candidates through large price tag acquisitions instead of developing them in house.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast